Chapter 2. Transient Ischemic Attacks

  1. Robert P. Lisak MD, FAAN, FRCP Parker Webber Chair Professor Chair Neurologist-in-Chief Chief2,3,
  2. Daniel D. Truong MD, FAAN Head4,
  3. William M. Carroll MBBS, MD, FRACP, FRCP(E) Head5 and
  4. Roongroj Bhidayasiri MD, FRCP Director6,7
  1. Samir H. Shah MD Clinical Fellow and
  2. Bruce Ovbiagele MD Associate Professor

Published Online: 18 MAY 2010

DOI: 10.1002/9781444317008.ch2

International Neurology: A Clinical Approach

International Neurology: A Clinical Approach

How to Cite

Shah, S. H. and Ovbiagele, B. (2009) Transient Ischemic Attacks, in International Neurology: A Clinical Approach (eds R. P. Lisak, D. D. Truong, W. M. Carroll and R. Bhidayasiri), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444317008.ch2

Editor Information

  1. 2

    Wayne State University School of Medicine, Detroit, MI, USA

  2. 3

    Detroit Medical Center, Harper University Hospital, Detroit, MI, USA

  3. 4

    The Parkinson and Movement Disorder Institute, Memorial Neuroscience Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, USA

  4. 5

    Sir Charles Gairdner Hospital, Nedlands, Perth, Australia

  5. 6

    Chulalongkorn Comprehensive Movement Disorders Center, Chulalongkorn University Hospital, Bangkok, Thailand

  6. 7

    University of California at Los Angeles, School of Medicine, Los Angeles, CA, USA

Author Information

  1. Stroke Center and Department of Neurology, UCLA School of Medicine, Los Angeles, CA, USA

Publication History

  1. Published Online: 18 MAY 2010
  2. Published Print: 11 SEP 2009

ISBN Information

Print ISBN: 9781405157384

Online ISBN: 9781444317008



  • transient ischemic attacks (TIA);
  • TIA - transient, neurological deficit sudden-onset due to brain ischemia;
  • TIA duration - less than 24 hours;
  • TIAs - neurological function focal loss;
  • TIA - subsequent ischemic stroke harbinger;
  • epidemiology - TIA incidence and prevalence;
  • pathophysiology - cerebral blood flow reduction leading to neuronal dysfunction;
  • TIA clinical features - transient monocular vision loss;
  • investigations - TIA patient hospitalization and risk stratification or managed;
  • non cardioembolic TIA treatment - asprin - antiplatelet agent


This chapter contains sections titled:

  • Introduction

  • Epidemiology

  • Pathophysiology

  • Clinical features

  • Investigations

  • Treatment/management

  • Further reading